title: [Cytoplasmic islet-cell antibodies (ICA) and cytoplasmic complement- fixing antibodies (CF-ICA) in patients with newly detected and short-lasting diabetes mellitus type 1].
abstract: The study aimed at assessing ICA and CF-ICA in the serum of patients with newly diagnosed and short-lasting diabetes mellitus type 1. Sixty patients with newly diagnosed diabetes type 1 (39 patients) and short-lasting diabetes of the same type (21 patients) aged between 2 and 34 years were classified. Anti-islet antibodies were detected with indirect immunoflourescence in specimens of fresh, frozen human pancreast in the tested group ICA were found in 53% of cases. At the time of diagnosis, ICA were found in 76% of children and in 14% of adult patients whereas respective data for diabetes mellitus lasting up to 2 years were 40% and 64%. Complement-fixing islet cytoplasmatic antibodies were found only in patients with ICA (47% of such cases). These antibodies were found in children with newly diagnosed diabetes mellitus (36%). In case of adults CF-ICA were detected in 7% of newly diagnosed diabetes mellitus cases and in 45% of cases with the disease lasting for 2 years. Titres of ICA ranged from 1:1 to 1:128 whereas titres CF-ICA from 1:1 to 1:8. No correlation between ICA titre and CF-ICA titre was noted.
authors: Kliniki Endokrynologii i Chorób Przemiany Materii PAM w Szczecinie.
authors: L
authors: L
authors: Majkowska
authors: S
authors: S
authors: Czekalski
authors: J
authors: J
authors: Skwira
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000032:analysis / Q000276:immunology*; D002648:Child; D003176:Complement C3 / Q000276:immunology*; D003168:Complement Fixation Tests; D003593:Cytoplasm / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D007515:Islets of Langerhans / Q000276:immunology* / Q000648:ultrastructure; D008297:Male; D013997:Time Factors
chemical_list: D001323:Autoantibodies; D003176:Complement C3
vernacular_title: Przeciwciała przeciwwyspowe cytoplazmatyczne ICA i cytoplazmatyczne wiazace dopełniacz CF-ICA u chorych na świezo rozpoznana i krótko trwajaca cukrzyce typu I.